OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI acquires startup Orchestra Bio to beef up its biotech business
Same story1 other outlet also reported this
- TechCrunch · AI··First·Reading now
OpenAI acquires AI biotech startup Orchestra Bio
- The Decoder··+11 h 58 min
OpenAI acquires Orchestra Bio to build AI agents for accelerating drug discovery
Adds:OpenAI mentions the average time to develop a drug in the US is 10 to 15 years.
In order of publication · later reports are added as they appear · Compared by AI from each outlet’s title and summary
In Brief
Posted:
1:35 PM PDT · October 20, 2026
OpenAI on Tuesday acquired a four-year-old AI biotech software startup called Orchestra Bio, the company announced on its website. Terms of the deal were not disclosed, but the startup had reportedly raised around $20 million as of 2025 from backers like Andreessen Horowitz, Atria, and 8VC.
Orchestra creates AI agents that help biotech companies manage the minutiae of drug-discovery operations, from tracking finances to resolving scheduling issues with clinical trials.
OpenAI says it’s adding Orchestra’s team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results. OpenAI has already won some big names as customers for Rosalind, including, it says, Moderna and Novo Nordisk.
The acquisition is a classic example of how the biggest AI labs (namely OpenAI and Anthropic) are building ever more software for the biggest industries, like pharma. In the startup world, there is an ongoing fear that at any moment, the labs will launch new features and become competitors. In this case, Orchestra is getting absorbed, rather than stomped out.
Source: TechCrunch · AI · techcrunch.com